Gabapentin-lactam (8-aza-spiro[5,4]decan-9-on; GBP-L) inhibits oxygen glucose deprivation-induced [3H]glutmate release and is a neuroprotective agent in amodel of acute retinal ischemia.
The modulation of the enhanced release of [3H]glutamate following ischemia-like conditions was studied in rat hippocampal slices using a superfusion system. Ischemia was simulated by a glucose-free medium equilibrated with 95% N2 and 5% CO2. In this model the potential neuroprotective effects of several substances on [3H]glutamate release induced by ischemia-like conditions were investigated. Gabapentin-lactam (8-aza-spiro-5,4-decan-9-on; GBP-L) was synthesised and patented in our laboratory. GBP-L (100 microM) reduced the oxygen glucose deprivation-induced [3H]glutamate release by 42.5%, CI95=[33.4%, 51.5%]. The KATP channel antagonist glibenclamide (1 microM) blocked this effect completely. The high antagonist potency was reflected by an apparent pA2-value of glibenclamide of 8.3, CI95=[6.8, 9.4]. Minoxidil sulfate (10 microM), a KATP channel opener, mimicked the effect of GBP-L (inhibition by 22.8%, CI95=[13.2%, 32.5%]). Similarly to its lactam, also gabapentin (100 microM) reduced the oxygen glucose deprivation-induced [3H]glutamate release by 30.6%, CI95=[15.5%, 45.7%], whereas the "antiglutamatergic" drug riluzole was ineffective. GBP-L and gabapentin were also tested in an in vivo model of acute retinal ischemia in rats. The intraocular pressure was elevated for 1 h above the systolic blood pressure. In the control group, 17.5%, CI95=[13%, 22%], of retinal ganglion cells had survived after 2 weeks. GBP-L doubled the number of surviving ganglion cells up to 35%, CI95=[27%, 43%], while gabapentin had no effect. This difference between gabapentin and its lactam may be due to different pharmacokinetic properties: In contrast to the gamma-amino acid gabapentin, GBP-L is uncharged and therefore might diffuse more easily through biological membranes, e.g. the plasma membrane, to get access to an intracellular locus of action. Thus, the neuroprotective properties in vivo and the diminished oxygen glucose deprivation-induced [3H]glutamate efflux in vitro of the presumed KATP channel agonist GBP-L suggest that this substance might be therapeutically applied in pathological situations induced by a rise in extracellular glutamate and/or neuronal cell death.
Sektion Klinische Neuropharmakologie der Neurologischen Universitätsklinik, Neurozentrum, Freiburg, Germany.
T
T
Jehle
W A
WA
Lagrèze
E
E
Blauth
R
R
Knörle
P
P
Schnierle
C H
CH
Lücking
T J
TJ
Feuerstein
D000465:Algorithms; D000818:Animals; D001372:Aza Compounds / Q000494:pharmacology*; D003292:Convulsants / Q000494:pharmacology*; D005947:Glucose / Q000502:physiology*; D018698:Glutamic Acid / Q000378:metabolism*; D007511:Ischemia; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010100:Oxygen / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D012039:Regional Blood Flow / Q000187:drug effects; D012160:Retina / Q000187:drug effects*; D012165:Retinal Ganglion Cells / Q000187:drug effects / Q000378:metabolism; D012171:Retinal Vessels / Q000187:drug effects*; D013141:Spiro Compounds / Q000494:pharmacology*
D001372:Aza Compounds; D003292:Convulsants; D018696:Neuroprotective Agents; D013141:Spiro Compounds; C404763:gabapentin-lactam; D018698:Glutamic Acid; D005947:Glucose; D010100:Oxygen